Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Abstract

We conclude that tumors with overexpression of the c-erbB-2 oncogene are less responsive to cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant therapy regimens than those with a normal amount of gene product.

Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridization

“…Assessment of the copy number of the Her-2neu gene and its expression has evolved as an important prognostic indicator in breast, ovarian, and uterine cancers. [35][36][37][38][39] The characteristic rearrangement of RARA with the PML (promyelocytic leukemia) gene on 15q22 has proven to be integral in the diagnosis and treatment of acute promyelocytic leukemia. [40][41][42] Since the cytogenetic findings of the current study and a review of the literature indicated that the 17p11-13 region likely harbors an oncogene of etiologic importance in aneurysmal bone cyst, efforts to further characterize the critically involved 17p breakpoint were conducted.…”

Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

“…More than 10 years after the first report by Slamon et al (1) showing the existence of a correlation between ERBB2 amplification and poor prognosis in breast carcinoma, the role of ERBB2 amplification/overexpression as an independent prognostic marker remains controversial, especially in node negative cases (3,5,8,15,16; for review, see 6, 7). Similarly, its predictive value regarding tumor response to treatment is still unclear (9 -14; for review, see 6, 7).…”

“…Several works suggest that this amplification/overexpression is associated with poor prognosis in breast carcinoma, especially in node positive cases (1-5; for review, see 6,7) and that it could be a marker of reduced response to chemotherapy (3,4,8,9; for review, 6, 7). Conversely, whereas some authors provided data suggesting that ERBB2 expression was a marker of preferential response to anthracycline-containing regimens (10 -11), others found no significant correlation (12)(13)(14).…”

An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression

“…ErbB2 is overexpressed in a proportion of human tumours arising from several di erent sites (Berchuck et al, 1990;Hall et al, 1990;Kern et al, 1990;Yokota et al, 1986;Yonemura et al, 1991). In the breast, the 20 ± 25% of cancers which overexpress the gene have a poorer prognosis (Borg et al, 1990;Gasparini et al, 1992;Press et al, 1993;Slamon et al, 1987;Wright et al, 1989) and are relatively resistant to hormonal treatment (Wright et al, 1992) and chemotherapy (Gusterson et al, 1992;Muss et al, 1994). In vitro, ERBB2 is a transforming oncogene, both in rodent ®broblasts (Di Fiore et al, 1987) and immortalised breast epithelial cell lines (D'Souza et al, 1993).…”